LACTOLOGY FOUNDATION

Timepidium bromide (ATC A03AB19) is a peripherally acting synthetic anticholinergic of the quaternary ammonium class, used as a gastrointestinal antispasmodic; data on its use in breastfeeding are extremely limited, so risk assessment must be extrapolated from class effects.medpedia.framar+5

Pharmacological profile

Timepidium bromide is classified under ATC A03AB19 as a synthetic anticholinergic, quaternary ammonium compound indicated for functional gastrointestinal disorders and visceral spasms. It acts as a muscarinic receptor antagonist, reducing smooth muscle tone and motility in the gastrointestinal tract and biliary system, thereby relieving spasmodic pain. The presence of a quaternary nitrogen limits blood–brain barrier penetration, so it is considered peripherally acting with minimal central nervous system effects.bbfarma+6

Therapeutic use and dosing context

Clinically, timepidium bromide is used for symptomatic treatment of convulsions and pain associated with motility disorders in conditions such as gastritis, gastric and duodenal ulcer, enteritis, and gallbladder disease. It belongs to the broader group of drugs for functional bowel and other functional gastrointestinal disorders within ATC class A03. Dosing regimens are product-specific and determined by a physician, with preparations available by prescription only in many jurisdictions.mims+3

Toxicology and safety profile

Human toxicology data for timepidium bromide are sparse, but adverse effects can be inferred from its anticholinergic mechanism. Common class-related side effects include dry mouth, constipation, blurred vision, urinary retention and, less frequently, tachycardia, all resulting from systemic muscarinic blockade. Because it is a quaternary ammonium compound with poor central penetration, central anticholinergic syndrome is unlikely at therapeutic doses, though peripheral toxicity may occur with overdose or in susceptible patients (e.g. those with glaucoma, prostatic hypertrophy, or severe bowel obstruction). Standard contraindications include hypersensitivity to the active substance or excipients and caution in patients with pre‑existing conditions that can be worsened by antimuscarinic effects.wikipedia+5

Environmental toxicity data (fish, daphnia, algae) are not available, underscoring the limited non‑clinical toxicology information publicly accessible. The safety of timepidium bromide during pregnancy and breastfeeding has not been systematically studied, and available summaries explicitly flag this knowledge gap.guidechem+1

Lactation risk assessment

There is no published, drug‑specific evidence on timepidium bromide excretion into human milk or its effects on breastfed infants. However, general principles for gastrointestinal antispasmodics during breastfeeding indicate that other antimuscarinic agents (e.g. hyoscine butylbromide, propantheline) can be used with caution, while dicycloverine is specifically discouraged because of a reported case of infant apnoea. Antimuscarinic drugs carry a theoretical risk of suppressing milk production due to systemic anticholinergic effects on lactation physiology, although robust clinical data are lacking.sps+2

Given its quaternary ammonium structure, oral bioavailability from milk to the infant is expected to be low, and the molecule is unlikely to cross the infant blood–brain barrier efficiently, which may limit central toxicity but not peripheral anticholinergic effects. In the absence of direct data, timepidium bromide should be considered a drug of uncertain lactation safety; use during breastfeeding is best reserved for situations where non‑antimuscarinic alternatives or better‑studied antispasmodics are unsuitable. If used, it is prudent to:medbox.iiab+3

• Prescribe the lowest effective dose for the shortest duration.healthdirect
• Time maternal dosing immediately after a feed to minimise infant exposure at peak maternal plasma levels.healthdirect
• Monitor the infant for adequate feeding, normal weight gain, bowel habit changes, excess sedation or irritability, and signs of anticholinergic effects (e.g. constipation, reduced sweating).sps+1

For mothers of neonates or preterm infants, the margin of safety is narrower; in such cases, preference should generally be given to better‑characterised agents or non‑pharmacological measures.sps+1

Practical recommendations for healthcare professionals

In clinical practice, timepidium bromide should be prescribed after weighing the benefit–risk ratio, particularly in breastfeeding women and patients with comorbidities affected by anticholinergic load. Health professionals should:synapse.patsnap+1

• Screen for contraindications (hypersensitivity, narrow‑angle glaucoma, urinary retention, severe constipation or ileus).medpedia.framar+1
• Counsel patients about typical anticholinergic adverse effects and advise prompt reporting of visual disturbances, urinary difficulties, severe constipation, or palpitations.synapse.patsnap
• In breastfeeding, consider alternative antispasmodics with more lactation data (e.g. hyoscine butylbromide, mebeverine, peppermint oil) before resorting to timepidium bromide.sps
• Document shared decision-making when lactating patients receive medicines with limited evidence, and arrange follow‑up to assess maternal symptom control and infant wellbeing.synapse.patsnap+2

An illustrative scenario is a breastfeeding woman with functional bowel spasm in whom non‑pharmacological measures and better‑studied antispasmodics have failed; short‑term timepidium bromide could be considered with close infant monitoring and explicit counselling about potential, though unquantified, risks.synapse.patsnap+2